Bepotastine controlled-release - Hanlim Pharmaceutical

Drug Profile

Bepotastine controlled-release - Hanlim Pharmaceutical

Alternative Names: Bepotastine sustained-release; HL 151

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanlim Pharmaceutical
  • Class Antiallergics; Antiasthmatics; Antihistamines; Antipruritics; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Pruritus
  • Phase I Perennial allergic rhinitis

Most Recent Events

  • 17 May 2017 Phase-III clinical trials in Pruritus in South Korea (PO) (NCT03317301)
  • 01 Feb 2016 Hanlim Pharm initiates enrolment in a phase I trail in Healthy volunteers in South Korea (NCT02686294)
  • 01 Jan 2016 Phase-I clinical trials in Perennial allergic rhinitis (In volunteers) in South Korea (PO, Controlled-release) (NCT02682745)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top